(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) shares are sliding more than 11 percent on Monday morning trade, in search of new support.
The company revealed positive Ibezapolstat microbiome data from its phase 2 a trial in clostridioides difficile infection. In a poster presentation at the Infectious Disease Society of America IDWeek 2021 virtual conference on September 29th the company revealed favorable microbiome changes included overgrowth of actinobacteria and fimicutes phylum species while on therapy. The company said the trial demonstrated 100 percent clinical cure and sustained clinical cure. Further, the company plans to evaluate pharmacokinetics and microbiome changes from baseline and continue to test for anti-recurrence microbiome properties seen in the Phase 1 trial, including the treatment-related changes in alpha diversity and bacterial abundance.
Currently, shares are at 4.60, down 11.70 percent from the previous close of $5.21 on a volume of 289,658. For the 52-week period, the shares have traded in a range of $3.71-$8.74 on average volume of 167,401.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.